RE:RE:RE:RE:RE:Upside to CRDonein: OK. I re-read. The only thing gating pre-BTD submission seems to be survival data for those 16 (14+2). I was confused by the part of the statement that said "... By introducing these optimizations in study 2, future reviews with the regulators will be more efficient..". I assumed that meant those optimization results are required to complete phase2 and a BTD application. You haven't come back with any timeline, especially given there's an unknown lab that has to validate what Theralase says. We can of course assume that this lab has unlimited time and resources and will ask "how high" when TLT says "jump". I've said mid Q1 several times. What's your take. My first purchase was 2009 or 2010. Longest ever hold, waiting to convert into best-ever but running out of patience each time they delay and dilute. What I don't pay attention to are the goofballs here who always seem to think it's sinful to question anything this company does. As I post here, I see one more raise. May the spin begin
Donein25 wrote: Why are you throwing numbers like 6 months or a year around? Read the NR. There are 16 total responders who were either CR or IR at 450 days. Do you really think it will take 6 months or a year to assess their status? Stop.